Editas Medicine (EDIT) Up 11.66% for June 23

Equities Staff  |

Today, Editas Medicine Inc (NASDAQ:EDIT) was up $1.41 to end the day Thursday at $13.50.

The company began the day at $12.22 and shares fluctuated between $13.54 and $12.05 with 2,107,293 shares trading hands.

Editas Medicine is averaging 1,714,085 shares traded over the last 30 days. They have fell 54.46% YTD.

Editas Medicine expects its next earnings on 2022-08-03.

For technical charts, analysis, and more on Editas Medicine visit the company profile.

About Editas Medicine Inc

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

To get more information on Editas Medicine Inc and to follow the company's latest updates, you can visit the company's profile page here: Editas Medicine Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content